Related Experiment Video

Updated: Mar 11, 2026

Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products
06:47

Measuring Volatile and Non-volatile Antifungal Activity of Biocontrol Products

Published on: December 5, 2020

7.4K

Novel antifungal agents: a patent review (2013 - present)

María Victoria Castelli1, Marcos Gabriel Derita1,2, Silvia Noelí López1

  • 1a Universidad Nacional de Rosario , CONICET, Farmacognosia, Facultad de Ciencias Bioquímicas y Farmacéuticas , Rosario , Santa Fe , Argentina.

Expert Opinion on Therapeutic Patents
|November 30, 2016
PubMed
Abstract

Insights

New antifungal compounds are urgently needed due to rising invasive fungal infections (IFI) and drug resistance. Recent patents show progress in developing novel antifungal agents with improved properties, but broader activity and specific mechanisms remain a priority.

Area of Science:

  • Mycology
  • Medicinal Chemistry
  • Pharmaceutical Sciences

Background:

  • Superficial fungal infections are common; invasive fungal infections (IFI) are increasing in immunocompromised individuals, posing a high mortality risk.
  • Current treatments like Amphotericin B, triazoles, and echinocandins have limitations due to resistant fungi and side effects.
  • There is an urgent need for novel therapeutic strategies to combat fungal diseases effectively.

Purpose of the Study:

  • To review patents granted between August 2013 and June 2016 for antifungal compounds.
  • To highlight advances in discovering new natural or synthetic antifungal agents.
  • To document improvements in existing patented antifungal structures.

Main Methods:

  • Patent literature review focusing on antifungal compounds.
  • Analysis of patents from August 2013 to June 2016.
  • Categorization of advancements by pharmaceutical companies and research groups.

Main Results:

  • Patents reveal progress in developing new antifungal compounds and analogs of existing drugs.
  • Advancements include compounds with broader spectrum activity, improved pharmacokinetics, and better bioavailability.
  • Several patented structures show modifications aimed at enhancing antifungal efficacy.

Conclusions:

  • The patent landscape indicates significant efforts in antifungal drug discovery and development.
  • While progress has been made, there is a continued need for antifungal compounds with broader activity and fungal-specific mechanisms of action.
  • Future research should prioritize agents with enhanced efficacy and reduced toxicity for treating invasive fungal infections.
Keywords:
Polyenesantifungal compoundsantifungal peptidesazole-based antifungal drugsfungal cell wall

More Related Videos

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

21.4K
Quantifying the Antifungal Activity of Peptides Against Candida albicans06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

3.0K

Related Concept Videos

Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
1.6K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
306
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
235
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
289